Wilson's T3+T2 Enhanced Protocol: Beyond the Cyclic T3 Approach
The Wilson's T3+T2 enhanced protocol begins where the original WT3 framework ends. Wilson's cyclic T3 protocol - developed by Dr. Denis Wilson and documented across decades of use in the bioenergetic research community - addressed a specific biochemical problem: the T4→T3 conversion bottleneck that leaves research subjects functionally hypothyroid despite adequate T4 supply. By delivering sustained-release T3 directly in a cyclic titration, the WT3 protocol bypasses the impaired deiodinase step and delivers the receptor-active hormone without depending on intact conversion from T4. That was the first-generation insight.
The enhanced protocol is the second-generation extension. It adds 3,5-T2 (3,5-diiodothyronine) as a paired daily dose at a 1:1 mcg ratio with T3, running the same titration ladder from start to target temperature and back down. The rationale is not that the WT3 protocol is flawed - it is that the WT3 protocol solves one conversion bottleneck while leaving a second one unaddressed. If the T4→T3 step is impaired by selenium deficiency and inflammation, the T3→T2 step is impaired by the same dysfunction in the same research subject. Supplementing T3 without addressing downstream T2 production delivers one half of the mitochondrial signaling picture. The enhanced protocol attempts to deliver both halves simultaneously.
Research Grade · Discreet Worldwide Shipping
Wilson's T3+T2 Combo
This article covers the mechanistic lineage from Wilson's original WT3 framework through the T3+T2 extension: what the original protocol does, what it does not address, why T2 represents a specific and complementary solution to the second bottleneck, how the 1:1 pairing fits into the titration architecture, and how the Wilson's T3+T2 Combo kit is structured to support the full titration ladder.
Research framing. This article reviews the Wilson's T3+T2 enhanced protocol from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.
Background: The Original Wilson's WT3 Protocol
The Wilson's Temperature Syndrome (WTS) framework rests on a specific clinical observation: a subset of chronically ill individuals maintain persistently subnormal oral body temperatures despite thyroid lab panels that fall within reference ranges. Dr. Wilson's hypothesis was that this temperature dysregulation reflected impaired conversion of T4 to the active hormone T3 - producing a tissue-level hypothyroid state that standard TSH and even free T4 testing would not detect. The full context of Wilson's Temperature Syndrome as a diagnostic and treatment framework is covered in the Wilson's Temperature Syndrome guide.
The WT3 protocol operationalizes this hypothesis with a structured cyclic titration. Starting at 7.5 mcg of sustained-release T3 every 12 hours, the protocol steps the dose upward in 7.5 mcg increments every 1-3 days, tracking oral body temperature at each step. The titration target is a sustained oral temperature of 98.6°F (37.0°C) held for 3 consecutive weeks - the sustained-temperature endpoint that Dr. Wilson proposed as evidence of receptor normalization. Once the target is held, the dose is tapered back down at the same 7.5 mcg / 1-3 day rate. The cyclic structure matters: the up-titration phase saturates thyroid hormone receptors and clears the reverse-T3 competition that has accumulated during the hypothyroid period; the taper allows the HPT axis to recalibrate.
The WT3 protocol's key pharmacological design is the use of sustained-release T3 rather than immediate-release liothyronine. Immediate-release T3 produces a sharp serum peak and a corresponding trough, which in the WT3 context can trigger cardiovascular symptoms on the upswing and leave receptor occupancy inadequate during the trough. SR-T3 flattens that curve, maintaining steadier receptor engagement throughout the 12-hour dosing interval. For a full review of the SR-T3 formulation rationale, see the sustained-release T3 complete guide.
The reverse-T3 clearing rationale is central to why the WT3 protocol uses high-dose exogenous T3. Reverse T3 is an inactive metabolite that competes with active T3 for nuclear receptor binding without activating those receptors. In chronic illness states characterized by elevated inflammation and DIO3 activity, rT3 accumulates and effectively occupies receptors that should be responding to active T3. The WT3 titration is designed to flood receptor sites with T3 at concentrations sufficient to displace rT3 and restore functional signaling. Once the receptor normalization is achieved and body temperature stabilizes, the hypothesis is that endogenous conversion can resume at a corrected setpoint. A detailed breakdown of the WT3 approach and its titration mechanics is available in the Wilson's WT3 protocol guide.
What the Original Protocol Doesn't Address
The WT3 protocol is an excellent solution to a specific problem: it bypasses the T4→T3 bottleneck by delivering T3 directly. What it does not address is the step that follows.
T3 is not the terminal product of thyroid hormone metabolism. Once T3 is present in peripheral tissues - whether produced endogenously from T4 or delivered exogenously as part of a WT3 regimen - the deiodinase system continues to process it. DIO1 acts on T3 to remove an outer-ring iodine, producing downstream diiodothyronine metabolites. The most metabolically significant of those downstream products is 3,5-T2, the thyroid metabolite that bypasses nuclear receptors entirely and binds directly to cytochrome c oxidase in the mitochondrial inner membrane.
The critical point is that the T3→T2 conversion bottleneck is created by the same enzymatic dysfunction that creates the T4→T3 bottleneck. DIO1 is a selenoprotein. Selenium deficiency degrades its activity. The same inflammatory cytokine environment that suppresses DIO1 function during the first conversion step suppresses DIO1 function during the second. A research subject undergoing a WT3 protocol is, by definition, a subject whose deiodinase function was impaired enough to justify the protocol in the first place. That same impairment affects the T3→T2 conversion step, meaning the exogenous T3 being delivered by the protocol may not be efficiently converted to T2 downstream.
The consequence is an incomplete signaling picture. T3 activates nuclear thyroid hormone receptors, drives genomic transcription, and works through the 6-48 hour cascade of gene expression changes that governs long-range metabolic programming. T2 activates cytochrome c oxidase directly, in real time, at the level of the mitochondrial electron transport chain. These are not redundant mechanisms - they operate on different substrates, through different binding sites, on different timescales. Delivering T3 without T2 in a subject with impaired T3→T2 conversion means the mitochondrial signaling layer remains undersupported even as the nuclear receptor layer is addressed.
This is the gap the enhanced T3+T2 protocol targets. The complete mechanistic explanation of why the same deiodinase dysfunction blocks both conversion steps simultaneously, and what that means for T3 protocol plateau patterns, is detailed in the T3→T2 conversion problem: why T3 protocols plateau - the foundational analysis that underpins the enhanced protocol's rationale.
The Case for Adding T2
Three independent lines of reasoning support adding 3,5-T2 to the standard WT3 titration:
Mitochondrial mechanism that T3 does not replicate. 3,5-T2 binds directly to subunit Va of cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain). This binding elevates the rate of aerobic respiration in minutes - a timeline incompatible with genomic signaling and reflecting direct enzymatic activation. T3 does not replicate this mechanism. T3's mitochondrial effects are indirect: T3 drives nuclear transcription of genes including mitochondrial biogenesis factors, but that pathway operates over days, not minutes. The cytochrome c oxidase pathway is T2's exclusive contribution to the protocol. Foundational documentation of this mechanism is in the complete 3,5-T2 research guide.
Independence from nuclear receptor sensitivity. In chronic illness states, nuclear receptor impairment can emerge as a secondary phenomenon alongside deiodinase dysfunction. Receptor downregulation, reduced cofactor availability for receptor-coactivator complexes, and epigenetic silencing of thyroid hormone response elements are all proposed mechanisms by which long-standing hypothyroid states can reduce the responsiveness of cells to T3 even when T3 is present. T2's cytochrome c oxidase pathway is independent of nuclear receptors. It does not require TRalpha or TRbeta occupancy to produce its mitochondrial effect. In a research context where receptor sensitivity may be partially compromised, T2 provides a mitochondrial activation pathway that does not depend on the receptor layer being fully functional.
Minimal HPT axis suppression. The dose-limiting concern in any T3 protocol is TSH suppression. T3 is a potent suppressor of the hypothalamic-pituitary-thyroid axis via TRbeta binding in the pituitary - which means escalating T3 carries inherent suppression risk at higher doses. 3,5-T2 binds thyroid hormone receptors at approximately 10 times lower affinity than T3 in animal models, producing correspondingly weaker TSH suppression per microgram. Adding T2 at a 1:1 ratio with T3 adds mitochondrial activation capacity without proportionally increasing HPT axis suppression. The net effect is a broader functional signal delivered at a lower total nuclear receptor burden than would be required if T3 alone were carrying the entire protocol.
Why 1:1 T3:T2 Ratio
The physiological argument for a 1:1 T3:T2 ratio by mass starts with what the deiodinase system produces when it is functioning normally. Under intact conversion, T3 that enters peripheral tissues is processed by DIO1 into downstream diiodothyronine products. The total T2 output relative to T3 substrate - across liver, kidney, and peripheral tissues - produces circulating T2 concentrations that, when measured in healthy subjects, are present in a mass ratio relationship to T3 that falls in the range of roughly 1:1 across the thyroid hormone metabolite pool, though the precise ratio varies by tissue, measurement method, and individual metabolic status.
The honest qualification is that "physiological 1:1" is a simplification. T2 circulates at much lower absolute concentrations than T3 in serum; the 1:1 comparison refers to the relationship in terms of what the deiodinase system produces from a given T3 input under intact conditions, not to the serum concentration ratio observed in standard thyroid panels. Different tissues have different local conversion efficiencies, different DIO1 expression levels, and different downstream T2 utilization rates. A single whole-body ratio is necessarily an approximation.
For protocol design purposes, 1:1 is a defensible simplification for two reasons. First, it matches the body's intended downstream product relationship at the conversion input level - a T3 molecule entering a DIO1-functional cell is processed into approximately one T2 equivalent by mass through the deiodination cascade. Second, 1:1 avoids the problem of under- or over-correction: a ratio significantly lower than 1:1 T2 leaves the mitochondrial signaling layer undersupported relative to the receptor layer; a ratio significantly higher than 1:1 risks delivering T2 at concentrations the body's endogenous system would not normally produce. The research community using the enhanced protocol framework has generally converged on 1:1 as the starting reference ratio, with individual titration adjustments made based on temperature response, tolerability, and symptom tracking.
The Enhanced Protocol: Titration with Paired T2
The enhanced protocol mirrors the classical WT3 cyclic titration architecture exactly, with one modification: at every step of the titration ladder, 3,5-T2 is dosed at the same microgram amount as T3. The dosing interval remains 12 hours. The temperature target remains the same 98.6°F (37.0°C) sustained for 3 consecutive weeks. The step duration remains 1-3 days per step. The taper mirrors the titration. Nothing in the structural logic of the WT3 protocol changes - the T2 addition is layered onto the existing architecture as a parallel supplementation track, not a redesign of the protocol mechanics.
View enhanced protocol titration schedule (research summary)
| Step | T3 dose (per 12h) | T2 dose (per 12h) | Days at this step |
|---|---|---|---|
| Start | 7.5 mcg | 7.5 mcg | 1-3 days |
| Step 2 | 15 mcg | 15 mcg | 1-3 days |
| Step 3 | 22.5 mcg | 22.5 mcg | 1-3 days |
| Step 4 | 30 mcg | 30 mcg | 1-3 days |
| Step 5 | 37.5 mcg | 37.5 mcg | 1-3 days |
| Step 6 | 45 mcg | 45 mcg | 1-3 days |
| Step 7+ | Continue +7.5 mcg per step | Matched 1:1 | Continue until temperature target |
The titration target remains the same as classical WT3: sustained oral body temperature ≥98.6°F (37.0°C) for 3 consecutive weeks. Taper down at the same +7.5 mcg / 1-3 day rate.
The cyclic structure inherited from the WT3 protocol - titrate up to temperature target, hold for 3 weeks, taper back down - is preserved unchanged in the enhanced version. The rationale for the cyclic architecture in the original WT3 protocol (receptor saturation on the way up, rT3 clearing at the peak hold, HPT axis recalibration on the way down) applies equally in the enhanced version. The T2 addition does not disrupt the cyclic logic; it supplements it by adding mitochondrial co-activation at each step of the cycle that would otherwise depend on intact T3→T2 conversion.
Reverse-T3 Clearing Extended to T2
The rT3-clearing mechanism is the operational center of the original WT3 protocol. The argument is that high-dose T3 floods nuclear receptor sites with sufficient concentration to competitively displace the rT3 that has been occupying those sites and blocking functional signaling. Sustained occupancy of receptors by active T3 for 3 consecutive weeks is proposed to reset the receptor sensitivity baseline and allow endogenous conversion to resume at a more favorable T3:rT3 ratio post-taper.
The enhanced protocol extends this logic to the mitochondrial layer. If rT3 clearing addresses the nuclear receptor bottleneck, the parallel T2 supplementation addresses the mitochondrial bottleneck: cytochrome c oxidase that has been operating below capacity due to inadequate endogenous T2 production is directly supplied with the ligand it would receive under intact conversion conditions. Just as the WT3 protocol saturates receptor sites to override the rT3 dominance pattern at the genomic level, the T2 component of the enhanced protocol saturates the cytochrome c oxidase pathway to override the T3→T2 conversion deficiency at the mitochondrial level.
Both bottlenecks are addressed simultaneously in the enhanced protocol - not sequentially. The nuclear receptor layer and the mitochondrial layer receive their respective signals in parallel, from the same twice-daily dose event. The 3-week sustained-temperature hold target captures both: nuclear receptor normalization requires sustained T3 occupancy; cytochrome c oxidase reactivation requires consistent T2 availability throughout the same period. The temperature endpoint serves as a composite marker for both layers of signaling being adequately restored.
The T3→T2 conversion problem and its relationship to the rT3 clearing mechanism is analyzed in detail in the T3→T2 conversion problem article, which documents why deiodinase dysfunction blocks both conversion steps through the same enzymatic pathway and why addressing the second bottleneck changes the plateau pattern observed in T3-only protocols.
Mitochondrial Co-Activation Rationale
The specific value of mitochondrial co-activation in the context of chronic illness research is not arbitrary. Mitochondrial dysfunction - defined broadly as impaired electron transport chain efficiency, reduced ATP production per unit oxygen consumed, elevated reactive oxygen species output, and impaired mitochondrial membrane potential - is a consistent finding across the research literature on chronic fatigue syndrome (ME/CFS), fibromyalgia, and post-viral syndromes. These conditions share a phenotypic cluster: disproportionate fatigue relative to exertion, non-restorative sleep, cognitive impairment with normal structural brain imaging, and metabolic rate dysregulation. The common thread in the bioenergetic research interpretation is that cellular energy production is insufficient to meet metabolic demand.
The relationship between thyroid hormone deficiency and mitochondrial dysfunction is bidirectional in the research literature. Impaired thyroid signaling reduces the transcription of mitochondrial biogenesis factors (PGC-1alpha and related targets are T3-responsive), reduces electron transport chain enzyme expression, and reduces the thermogenic capacity of brown adipose tissue. Mitochondrial dysfunction in turn reduces the cell's capacity to respond to thyroid hormones, creating a negative feedback loop between the two systems. Addressing only the genomic layer of thyroid signaling - via T3 alone - partially breaks this loop: T3 restores gene transcription programs that support mitochondrial biogenesis over days to weeks. The cytochrome c oxidase activation layer - which T2 addresses directly - provides an acute bioenergetic signal that operates independently of and in parallel with that longer-range genomic recovery.
For research subjects whose chronic illness presentation involves prominent fatigue, temperature dysregulation, and metabolic rate suppression - the classic WTS-adjacent profile - the combination of T3 for genomic receptor activation and T2 for direct mitochondrial activation addresses the two primary layers of the signaling deficit simultaneously. Neither alone is sufficient to fully recapitulate the complete thyroid hormone signal that intact conversion from T4 through T3 to T2 would produce.
What Researchers Discuss in Practice
The bioenergetic research community discussion around the enhanced protocol covers several practical dimensions that arise in structured protocol contexts. The following summarizes the working positions most consistently represented in that discussion.
Starting dose and tolerability. The 7.5 mcg T3 + 7.5 mcg T2 starting step is generally considered a low-burden entry point, consistent with standard WT3 starting doses. T2's shorter half-life and weaker TSH suppression potency mean that the T2 component at 7.5 mcg adds minimal systemic burden at initiation. Researchers tracking resting heart rate, blood pressure, and body temperature as primary monitoring endpoints during WT3 protocols typically add these same metrics when running the enhanced version.
Titration tempo. The 1-3 day step duration inherited from the original WT3 protocol applies to the enhanced version. Researchers who found that 3 days per step was more tolerable in WT3 generally continue using 3-day steps in the enhanced version. The T2 component does not appear to independently require a different step tempo in the research community discussion - the primary titration driver remains the T3 component and the temperature response.
When to add T2 - from day 1 vs. mid-protocol. There is a split in research community discussion on this point. The enhanced protocol as described in this article starts T2 from day 1 alongside T3, based on the premise that the T3→T2 conversion deficit exists from the outset and the mitochondrial layer needs co-activation throughout the entire protocol. An alternative position - reported in some forum discussions - is to run the first WT3 cycle without T2 to establish a tolerance baseline, then add T2 from the second cycle onward. Neither position has clinical trial support; the from-day-1 approach is more consistent with the underlying conversion-deficit rationale.
View practical schedule considerations for adding T2 mid-protocol (research discussion)
When adding T2 mid-protocol (e.g., at Step 3 or Step 4 of an existing WT3 titration), the common research-community approach is to add T2 at the microgram amount matching the current T3 step rather than starting T2 at 7.5 mcg and re-running a separate T2 ladder. So if the current T3 dose is 22.5 mcg, T2 is introduced at 22.5 mcg on the same day and continues matched 1:1 through the remaining titration steps and taper. This avoids running two asynchronous titration tracks and preserves the 1:1 ratio from the point of T2 introduction onward.
Plateau within the enhanced protocol. Research subjects who plateau within the enhanced protocol - where further T3+T2 dose increases are not producing temperature target advancement - face the same diagnostic question as in the WT3 protocol: is the plateau driven by adrenal axis insufficiency, by inadequate selenium co-factor, by cortisol suppression of deiodinase, or by receptor desensitization? The enhanced protocol does not eliminate these confounders. The standard WT3 plateau workup (cortisol, ferritin, selenium, adrenal function screening) applies equally.
Discontinuing T2. The taper logic mirrors WT3: T3 and T2 are tapered together at the 7.5 mcg/step rate. There is no protocol-specific rationale for tapering T2 separately from T3; the paired dosing structure is maintained through the full taper.
The Wilson's T3+T2 Combo Kit
The Wilson's T3+T2 Combo is structured specifically to support the full WT3 titration ladder at 1:1 T3:T2 pairing. The kit contains four capsule strengths that map directly to the titration steps:
- SRT3+T2-7.5 - 7.5 mcg T3 + 7.5 mcg T2 per capsule (starting step)
- SRT3+T2-15 - 15 mcg T3 + 15 mcg T2 per capsule (Step 2)
- SRT3+T2-22.5 - 22.5 mcg T3 + 22.5 mcg T2 per capsule (Step 3)
- SRT3+T2-45 - 45 mcg T3 + 45 mcg T2 per capsule (Step 6 / upper range)
Each capsule delivers the T3 and T2 components in a single unit at the 1:1 mcg ratio. The T3 component is formulated as sustained-release, consistent with the WT3 protocol requirement for flat serum curves and consistent receptor occupancy across the 12-hour dosing interval.
The excipient profile is HPMC (hydroxypropyl methylcellulose) and MCC (microcrystalline cellulose) only. This clean formulation is specifically relevant for research populations using these compounds in chronic illness contexts - mast cell activation syndrome (MCAS), histamine intolerance, and chemical sensitivity presentations are common co-morbidities in the WTS-adjacent research population, and a minimal-excipient profile reduces the likelihood of confounding reactions to inactive ingredients.
The four strengths cover the titration from the 7.5 mcg starting step through the 45 mcg upper-range step. Steps between the provided strengths can be handled by combining capsules: Step 4 (30 mcg) is two SRT3+T2-15 capsules; Step 5 (37.5 mcg) is one SRT3+T2-22.5 plus one SRT3+T2-15. For researchers beginning with a single strength to assess tolerability at the entry level, the SRT3+T2-15 is available as a standalone product at the Step 2 dose.
The complete kit design reflects the assumption that a researcher running the enhanced protocol will work through multiple titration steps - having all four strengths available from the start means the titration can proceed without sourcing delays at intermediate steps.
Researchers requiring the full T3+T2 enhanced protocol ladder can access the Wilson's T3+T2 Combo at the product page.
Honest Framing: What's Established vs Theoretical
Established:
Wilson's Temperature Syndrome and the WT3 cyclic T3 protocol are documented concepts in the bioenergetic research community, with published descriptions in the peer-reviewed literature and decades of use in clinical research and self-experimentation contexts. 3,5-T2 (3,5-diiodothyronine) binds cytochrome c oxidase at subunit Va and acutely stimulates mitochondrial electron transport chain activity - this is established in multiple peer-reviewed studies from Goglia, Lanni, and collaborators beginning with the 1994 FEBS Letters publication. Type 1 deiodinase (DIO1) is the primary enzyme for T3 catabolism in peripheral tissues and is involved in producing diiodothyronine downstream products from T3. DIO1 is a selenoprotein whose activity degrades under selenium deficiency and inflammatory signaling.
Theoretical / hypothesis:
The Wilson's T3+T2 enhanced protocol as a specific clinical or research intervention - with defined dose steps, temperature targets, and outcome expectations - represents a hypothesis built from established biochemical components, not a clinically validated protocol. There are no randomized controlled trials of T3+T2 paired cycling in Wilson's Temperature Syndrome or analogous populations. The dose tables presented in this article represent research-community working frameworks, not evidence-based clinical dosing guidelines. The T3→T2 conversion bottleneck hypothesis - while mechanistically coherent - has not been directly tested in a controlled study design in the chronic illness population. The inference that adding T2 to a WT3 protocol improves outcomes over WT3 alone is a logical extrapolation from the mechanistic data, not a finding from a comparative trial.
Not endorsed by mainstream endocrinology
Wilson's Temperature Syndrome is not recognized as a formal diagnosis in mainstream endocrinology. The American Thyroid Association and equivalent professional bodies do not endorse the WT3 protocol, cyclic T3 therapy outside of specific clinical indications, or the use of 3,5-T2 supplementation in any clinical context. The enhanced T3+T2 protocol operates entirely outside established clinical guidelines. Researchers using these compounds do so in a context where the supporting evidence is mechanism-based and community-reported rather than guideline-endorsed.
Frequently Asked Questions
What is the Wilson's T3+T2 enhanced protocol?
The Wilson's T3+T2 enhanced protocol is an extension of the classical Wilson's WT3 cyclic T3 protocol that adds 3,5-diiodothyronine (3,5-T2) at a 1:1 mcg ratio with T3 at every step of the titration ladder. The enhanced protocol is based on the premise that the T4→T3 and T3→T2 conversion bottlenecks are caused by the same deiodinase dysfunction, and that bypassing both simultaneously - by supplementing both T3 and T2 directly - produces a more complete thyroid signaling profile than T3 alone.
Why add T2 to the classical Wilson's WT3 protocol?
The classical WT3 protocol bypasses the T4→T3 conversion bottleneck. It does not bypass the T3→T2 conversion bottleneck. T3 must be converted to 3,5-T2 by DIO1 to supply the mitochondrial cytochrome c oxidase pathway. In research subjects whose DIO1 activity is impaired by selenium deficiency or inflammation - the same conditions that justify the WT3 protocol - T3→T2 conversion is impaired by the same mechanism. Adding T2 directly supplies the mitochondrial activation signal that impaired conversion would otherwise leave undelivered. The detailed mechanistic argument is in the T3→T2 conversion problem article.
What's the recommended dose of T2 in the enhanced protocol?
In the enhanced protocol framework, T2 is dosed at a 1:1 ratio with T3 at each titration step - starting at 7.5 mcg T2 per 12h alongside 7.5 mcg T3 per 12h and stepping up in parallel. The Wilson's T3+T2 Combo delivers pre-formulated capsules at each step strength (7.5, 15, 22.5, and 45 mcg per capsule) with the 1:1 ratio built in. Note that specific dosing decisions are outside the scope of this research summary.
Does T2 suppress TSH like T3 does?
3,5-T2 has approximately 10 times lower thyroid hormone receptor affinity than T3 in animal models, which translates to substantially weaker HPT axis suppression per microgram. Adding T2 at the 1:1 ratio with T3 does not proportionally double TSH suppression. This is one of the pharmacological features that makes T2 an attractive adjunct to T3 protocols: it adds mitochondrial activation capacity without equivalent HPT axis burden.
Should I start T2 from day 1 or add it mid-protocol?
The enhanced protocol as described here starts T2 from day 1 alongside T3, based on the rationale that T3→T2 conversion is impaired throughout the protocol and mitochondrial co-activation is relevant from the beginning. An alternative approach documented in research community discussions starts the first WT3 cycle without T2 to establish a T3 tolerability baseline and adds T2 from the second cycle. Both approaches have been reported; the from-day-1 approach is more consistent with the conversion-deficit rationale that underlies the enhanced protocol.
How long does the enhanced protocol take?
Duration follows the same framework as the classical WT3 protocol - the endpoint is a sustained oral body temperature of 98.6°F (37.0°C) held for 3 consecutive weeks, followed by a full taper. How long it takes to reach the temperature target depends on the individual's baseline temperature, titration step pace (1-3 days per step), and the dose required to reach target. Total protocol duration commonly ranges from 6 to 16 weeks, consistent with the WT3 literature.
Is the enhanced protocol safe for someone on T4 (levothyroxine)?
Combining exogenous T3 with levothyroxine requires awareness of total thyroid hormone load - T4 continues converting to T3 in the background while exogenous T3 and T2 are added on top. The research community discussion around running WT3 alongside ongoing T4 therapy generally recommends reducing or pausing T4 for the duration of the cyclic T3 protocol to avoid compounding TSH suppression. This is a research-community working position, not clinical guidance - researchers considering this combination should review the WT3+T4 interaction discussion in detail and consult relevant literature.
Where do I get research-grade T3+T2 with the 1:1 ratio?
The Wilson's T3+T2 Combo provides research-grade SR-T3+T2 capsules at the 1:1 mcg ratio in the four strengths that map to the WT3 titration ladder: 7.5, 15, 22.5, and 45 mcg. The entry-strength SRT3+T2-15 is also available as a standalone product.
Closing Note
The Wilson's T3+T2 enhanced protocol represents the logical next extension of the WT3 framework for the chronic-illness research context. Where the original protocol solved the T4→T3 conversion problem, the enhanced version addresses both conversion bottlenecks simultaneously - T3 for receptor activation, T2 for direct mitochondrial co-activation, at a 1:1 ratio that reflects the body's intended downstream product relationship under intact deiodinase function.
The mechanistic case for the extension is built on three bodies of evidence: the established cytochrome c oxidase binding mechanism documented for 3,5-T2, the enzymatic overlap between the T4→T3 and T3→T2 conversion steps, and the consistent finding of mitochondrial dysfunction in the chronic illness presentations that WTS-adjacent protocols are designed for. Why the same deiodinase dysfunction blocks both steps is the subject of the T3→T2 conversion problem analysis, which provides the foundational mechanistic support for the enhanced protocol's rationale.
The Wilson's T3+T2 Combo is designed for researchers running the full enhanced protocol titration. For researchers exploring the broader T3+T2 landscape, the complete catalog covers the available SR-T3, T2, and combination formulations.